Citations

Clear

3942 citation(s) found for "To, Van".

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet‐Loiseau, Hervé , Masszi, Tamás , Viterbo, Luísa, Pour, Luděk, Palumbo, Antonio , Cavo, Michèle , Langer, Christian , Pluta, Andrzej, Nagler, Arnon , Kumar, Shaji , Ben‐Yehuda, Dina, Miguel, Jesús F. San , Berg, Deborah, Lin, Jianchang , Velde, Helgi van de , Esseltine, Dixie‐Lee, Bacco, Alessandra Di , Moreau, Philippe , Richardson, Paul G. , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Bahlis, Nizar Jacques , Chng, Wee Joo , Ganly, Peter S. , Rajkumar, S. Vincent , Esseltine, Dixie‐Lee, Richardson, Paul Gerard Guy

Mayo Clinic

Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618

10.1182/blood-2017-06-791228 | PMID 29054911 Get It

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.
[P4–179]: ASPECTS OF SUBJECTIVE COGNITIVE DECLINE THAT PREDICT INCIDENT MCI IN THE MAYO CLINC STUDY OF AGING
Hagen, Clinton E., Edwards, Kelly K., Swenson-Dravis, Dana M., Roberts, Rosebud O., Petersen, Ronald C. , Harten, Argonde C. van , Mielke, Michelle M. , Knopman, David S. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_28 | Pages: No page available

10.1016/j.jalz.2017.06.2046 Get It

[O4–02–02]: POLY‐GP DIPEPTIDE REPEATS AND NEUROFILAMENT LIGHT CHAIN AS BIOMARKERS IN PRESYMPTOMATIC AND SYMPTOMATIC FRONTOTEMPORAL DEMENTIA CAUSED BY C9ORF72 REPEAT EXPANSIONS
Meeter, Lieke , Sias, Ana C. , Boxer, Adam L. , Laforce, Robert, Bocchetta, Martina , Petrucelli, Leonard , Lee, Suzee, Gendron, Tania F. , Jiskoot, Lize C. , Graff, Caroline , Sánchez‐Valle, Raquel , Pijnenburg, Yolande A.L. , Benussi, Luisa , Ghidoni, Roberta , Borroni, Barbara , Laforce, Robert , Cardoso, M. Jorge , Ourselin, Sébastien , Cash, David M. , Rohrer, Jonathan D. , Swieten, John C. van , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_25 | Pages: No page available

10.1016/j.jalz.2017.07.425 Get It

Right Heart Dysfunction and Failure in Heart Failure with Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology
Gorter, Thomas M. , Veldhuisen, Dirk J. van , Borlaug, Barry A. , Čelutkienė, Jelena , Crespo‐Leiro, María G. , Guazzi, Marco , Harjola, Veli‐Pekka, Heymans, Stéphane , Hill, Loreena , Lund, Lars H. , Mebazaa, Alexandre , Mueller, Christian, Paulus, Walter J. , Pieske, Burkert , Piepoli, Massimo , Seferović, Petar , Solomon, Scott D. , Shah, Sanjiv J. , Wachter, Rolf , Tschöpe, Carsten , Boer, Rudolf A. de , de Boer, Rudolf A , Borlaug, Barry A , Shah, Sanjiv J , Heymans, Stephane , Bauersachs, Johann , Coats, Andrew J.S. , Harjola, Veli‐Pekka , Lainščak, Mitja , Lam, Carolyn S.P. , Lyon, Alexander R. , Ruschitzka, Frank T. , Rutten, Frans Hendrik , Solomon, Scott David , Triposkiadis, Filippos K. , Tschöpe, Carsten , Celutkiene, Jelena , Crespo-Leiro, Maria Generosa

Mayo Clinic

European Journal of Heart Failure | October 17, 2017 | Volume: 20 | Issue: 1 | Pages: 16-37

10.1002/ejhf.1029 | PMID 29044932 Get It

Abstract There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine
Sterner, Rosalie M. , Kremer, Kimberly N. , Al‐Kali, Aref , Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Wijnen, André J. van , Hedin, Karen E. , Kaufmann, Scott H. , van Wijnen, Andre J , Westendorf, Jennifer J.

Mayo Clinic

Oncotarget | October 12, 2017 | Volume: 8 | Issue: 55 | Pages: 94569-94579

10.18632/oncotarget.21809 | PMID 29212250 Get It

Physiological Dead Space and Arterial Carbon Dioxide Contributions to Exercise Ventilatory Inefficiency in Patients with Reduced or Preserved Ejection Fraction Heart Failure
Iterson, Erik H. Van , Johnson, Bruce D. , Borlaug, Barry A. , Olson, Thomas P. , Van Iterson, Erik H , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | October 8, 2017 | Volume: 19 | Issue: 12 | Pages: 1675-1685

10.1002/ejhf.913 | PMID 28990307 Get It

Abstract Aims Patients with heart failure (HF) with reduced (HFrEF) or preserved (HFpEF) ejection fraction demonstrate an increased ventilatory equivalent for carbon dioxide (V̇E/V̇CO2) slope. The physiological correlates of the V̇E/V̇CO2 slope remain unclear in the two HF phenotypes. We hypothesized that changes in the physiological dead space to tidal volume ratio (VD/VT) and arterial CO2 tension (PaCO2) differentially contribute to the V̇E/V̇CO2 slope in HFrEF vs. HFpEF. Methods and results Adults with HFrEF (n = 32) and HFpEF (n = 27) [mean ± standard deviation (SD) left ventricular ejection fraction: 22 ± 7% and 61 ± 9%, respectively; mean ± SD body mass index: 28 ± 4 kg/m2 and 33 ± 6 kg/m2, respectively; P < 0.01] performed cardiopulmonary exercise testing with breath-by-breath ventilation and gas exchange measurements. PaCO2 was measured via radial arterial catheterization. We calculated the V̇E/V̇CO2 slope via linear regression, and VD/VT = 1 − [(863 × V̇CO2)/(V̇E × PaCO2)]. Resting VD/VT (0.48 ± 0.08 vs. 0.41 ± 0.11; P = 0.04), but not PaCO2 (38 ± 5 mmHg vs. 40 ± 3 mmHg; P = 0.21) differed between HFrEF and HFpEF. Peak exercise VD/VT (0.39 ± 0.08 vs. 0.32 ± 0.12; P = 0.02) and PaCO2 (33 ± 6 mmHg vs. 38 ± 4 mmHg; P < 0.01) differed between HFrEF and HFpEF. The V̇E/V̇CO2 slope was higher in HFrEF compared with HFpEF (44 ± 11 vs. 35 ± 8; P < 0.01). Variance associated with the V̇E/V̇CO2 slope in HFrEF and HFpEF was explained by peak exercise VD/VT (R2 = 0.30 and R2 = 0.50, respectively) and PaCO2 (R2 = 0.64 and R2 = 0.28, respectively), but the relative contributions of each differed (all P < 0.01). Conclusions Relationships between the V̇E/V̇CO2 slope and both VD/VT and PaCO2 are robust, but differ between HFpEF and HFrEF. Increasing V̇E/V̇CO2 slope appears to be strongly explained by mechanisms influential in regulating PaCO2 in HFrEF, which contrasts with the strong role of increased VD/VT in HFpEF.
Impact of TBI on caregivers of veterans with TBI: Burden and interventions
Malec, James F. , Houtven, Courtney H. Van , Tanielian, Terri , Atizado, Adrian, Dorn, M

Mayo Clinic

Brain Injury | October 5, 2017 | Volume: 31 | Issue: 9 | Pages: 1235-1245

10.1080/02699052.2016.1274778 | PMID 28981343 Get It

Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007—2015: A Serial, Cross‐sectional Study
Hof, Jeremy Van’t , Duval, Sue , Walts, Adrienne, Kopecky, Stephen L. , Luepker, Russell V. , Hirsch, Alan T.

Mayo Clinic

Journal of the American Heart Association | October 4, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006328 | PMID 28974502 Get It

Background No previous study has evaluated the impact of past US Preventive Services Task Force statements on primary prevention ( PP ) aspirin use in a primary care setting. The aim of this study was to evaluate temporal changes in PP aspirin use in a primary care population, stratifying patients by their 10‐year global cardiovascular disease risk, in response to the 2009 statement. Methods and Results This study estimated biannual aspirin use prevalence using electronic health record data from primary care clinics within the Fairview Health System (Minnesota) from 2007 to 2015. A total of 94 270 patient encounters had complete data to estimate a 10‐year cardiovascular disease risk score using the 2013 American College of Cardiology/American Heart Association global risk estimator. Patients were stratified into low‐ (<10%), intermediate‐ (10–20%), and high‐ (≥20%) risk groups. Over the 9‐year period, PP aspirin use averaged 43%. When stratified by low, intermediate and high risk, average PP aspirin use was 41%, 63%, and 73%, respectively. Average PP aspirin use decreased after the publication of the 2009 US Preventive Services Task Force recommendation statement: from 45% to 40% in the low‐risk group; from 66% to 62% in the intermediate‐risk group; and from 76% to 73% in the high‐risk group, before and after the guideline. Conclusions Publication of the 2009 US Preventive Services Task Force recommendation was not associated with an increase in aspirin use. High risk PP patients utilized aspirin at high rates. Patients at intermediate risk were less intensively treated, and patients at low risk used aspirin at relatively high rates. These data may inform future aspirin guideline dissemination.